SELENIOUS ACID Drug Patent Profile

When do Selenious Acid patents expire, and what generic alternatives are available?

Selenious Acid is a drug marketed by Am Regent, Aspiro, Cipla, Fresenius Kabi Usa, Gland, Kindos, Rk Pharma, and Sun Pharm. and is included in eight NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has six patent family members in six countries.

The generic ingredient in SELENIOUS ACID is selenious acid. Two suppliers are listed for this compound. Additional details are available on the selenious acid profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Selenious Acid

A generic version of SELENIOUS ACID was approved as selenious acid by AM REGENT on April 30^th, 2019.

Summary for SELENIOUS ACID

International Patents:	6
US Patents:	2
Applicants:	8
NDAs:	8
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SELENIOUS ACID

Paragraph IV (Patent) Challenges for SELENIOUS ACID

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SELENIOUS ACID	Intravenous Solution	selenious acid	600 mcg/10 mL	209379	11	2024-06-11

US Patents and Regulatory Information for SELENIOUS ACID

SELENIOUS ACID is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Am Regent	SELENIOUS ACID	selenious acid	SOLUTION;INTRAVENOUS	209379-003	Aug 30, 2021	AP	RX	Yes	Yes	12,150,957
Aspiro	SELENIOUS ACID	selenious acid	SOLUTION;INTRAVENOUS	219633-001	Jun 11, 2025	AP	RX	No	No
Am Regent	SELENIOUS ACID	selenious acid	SOLUTION;INTRAVENOUS	209379-002	Jan 25, 2021	AP	RX	Yes	Yes	11,998,565		Y
Gland	SELENIOUS ACID	selenious acid	SOLUTION;INTRAVENOUS	219629-001	Jul 8, 2025	AP	RX	No	No
Aspiro	SELENIOUS ACID	selenious acid	SOLUTION;INTRAVENOUS	219633-002	Jun 11, 2025	AP	RX	No	No
Sun Pharm	SELENIOUS ACID	selenious acid	SOLUTION;INTRAVENOUS	219547-001	Feb 20, 2025	AP	RX	No	No
Rk Pharma	SELENIOUS ACID	selenious acid	SOLUTION;INTRAVENOUS	218536-001	Dec 31, 2025	AP	RX	No	No

International Patents for SELENIOUS ACID

See the table below for patents covering SELENIOUS ACID around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	4175615
China	116096423
South Korea	20230058047
Australia	2021300384
World Intellectual Property Organization (WIPO)	2022006426
Canada	3186578

Selenious Acid (H₂SeO₃) in Pharmaceutical Markets: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Selenious acid (H₂SeO₃) is an inorganic selenium compound primarily used in the manufacture of nutritional supplements, pharmaceuticals, and industrial applications such as corrosion inhibitors. Despite its niche industrial footprint, recent advances in selenium-based therapeutics have stimulated renewed interest in its pharmaceutical potential. This report evaluates the current market landscape, identifies key factors influencing its investment appeal, and forecasts the financial trajectory over the upcoming decade.

---

Introduction

• Definition: Selenious acid is a selenium oxide hydrate with notable antioxidant and enzyme cofactor properties.
• Applications: Mainly used in dietary supplements, anti-cancer research, and as a reagent in chemical synthesis.
• Regulatory Status: Approved as a dietary supplement ingredient in various regions but faces regulatory scrutiny due to toxicity concerns at high doses.

---

Market Overview

Aspect	Details
Current Market Size (Global, 2022)	Estimated at USD 50 million, with a growth rate of approximately 4.8% annually (CAGR 2023–2033)
Key Markets	North America (45%), Europe (30%), Asia-Pacific (25%)
Major Players	FMC Corporation, DuPont, Corden Pharma, established chemical suppliers with pharmaceutical divisions

---

Investment Scenario

1. Market Drivers

• Growing Interest in Selenium-based Therapeutics: Emerging research on selenium’s role in cancer prevention and immune support boosts demand.
• Nutritional Supplement Industry Expansion: The global dietary supplements market projected to reach USD 228 billion (2024), with selenium components gaining popularity.
• Industrial Applications: Increasing use in corrosion inhibitors and catalysts supports ancillary revenue streams.

2. Market Challenges

• Toxicity and Safety Regulation: Narrow therapeutic window necessitates careful dosing; regulatory agencies (FDA, EMA) impose strict limits, influencing manufacturing costs and product approvals.
• Supply Chain Constraints: Selenium sourcing is geographically concentrated; geopolitical factors can cause supply volatility.
• Competitive Alternatives: Other selenium compounds (selenides, selenates) and organic selenium derivatives may offer safer or more effective options.

3. Investment Opportunities

Opportunity Area	Description	Risk Level	Potential Return
R&D in Selenium-based Drugs	Developing targeted therapeutics	High	High
Nutraceutical Formulations	Supplements with optimized bioavailability	Medium	Moderate
Manufacturing Capacity Expansion	Scaling synthesis processes	Low/Medium	Stable

4. Funding & Policy Environment

• Growing public health initiatives aim to integrate selenium supplementation.
• Policies favoring personalized medicine may incentivize research involving selenious acid derivatives.

---

Market Dynamics and Trends

Dynamic Factor	Impact	Source/Trend
Increasing R&D Investment	Accelerates novel drug development	NIH, EU funding programs
Consumer Trends Toward Natural Supplements	Drives demand for selenium-enriched products	Mintel, Euromonitor reports
Regulatory Landscape	Restricts high-dose applications; encourages standardization	FDA Guidance (2022), EMA Review (2023)
Manufacturing Innovations	New catalytic processes reducing costs	TechChem Quarterly (2022)
Emerging Markets	Asia-Pacific experiencing rapid growth	BCC Research (2023)

---

Financial Trajectory Forecast (2023–2033)

Year	Predicted Market Size (USD Million)	Annual Growth Rate (CAGR)	Key Factors
2023	50	—	Base year, moderate R&D activities
2024	53	4.8%	Increased nutraceutical demand
2028	75	7.1%	Broadened applications, new drug pipelines
2033	120	8.5%	Expansion into precision medicine and therapeutics

Note: Assumes steady R&D funding, regulatory approvals, and stable supply conditions. Market driven by both pharmaceutical innovations and supplement industries.

---

Comparison with Similar Compounds

Compound	Uses	Regulatory Status	Market Size (2022)	Notes
Selenides	Organic selenium derivatives	Similar	USD 200 million	Alternative therapeutic agents
Selenates	Supplements, agriculture	Approved	USD 300 million	Higher bioavailability in some formulations
Selenocysteine	Natural enzyme cofactor	Research stage	Niche	Potential for targeted drugs

---

Regulatory Policies and Approvals

Region	Regulatory Body	Status	Notable Regulations
United States	FDA	Dietary supplement approval, caution on high doses	GRAS status for certain formulations, safety guidelines for selenium intake (55 μg/day recommended)
European Union	EMA	Novel food authorization for supplements	Risk assessments emphasizing toxicity thresholds
China	NMPA	Limited approval for nutraceuticals	Focus on controlled dosing

---

Strategic Considerations for Investors

• Focus on R&D: Early-stage investments in selenium pharmacology hold high risk but offer significant upside with successful drug development.
• Partnerships: Collaborations with biotech firms and academic institutions support pipeline development.
• Regulatory Navigation: Investing in compliant manufacturing and standardization enhances market access.
• Diversification: Combining nutraceutical and pharmaceutical strategies mitigates sector-specific risks.

---

Deep Dive: Comparison with Market Competitors

Company	Focus Area	Investment Stage	Market Share (Estimated)	Notable Initiatives
FMC Corporation	Industrial + pharma	Established	~25%	Expanding selenium derivatives portfolio
Corden Pharma	Contract manufacturing	Active	N/A	Focused on GMP-grade selenious acid
In-house biotech ventures	Therapeutic R&D	Early	Niche	Investigating selenium in cancer therapy

---

FAQs

Q1: What are the main drivers for growth in the selenious acid market?
A1: Growing research into selenium’s health benefits, expansion of dietary supplement consumption, and increasing pharmaceutical R&D targeting selenium’s therapeutic potential drive market growth.

Q2: What are the primary regulatory hurdles facing selenious acid?
A2: Strict safety limits on selenium intake, toxic potential at high doses, and the need for rigorous standardization in manufacturing regulate its use, especially in pharmaceuticals.

Q3: How does supply chain volatility impact investments in selenious acid?
A3: Concentration of selenium sources in few geographic regions (e.g., Central Asia, South Africa) can cause price fluctuations and supply disruptions, requiring diversified sourcing strategies.

Q4: What differentiates selenious acid from other selenium compounds?
A4: Its water solubility and specific reactivity profile make it suitable as an industrial reagent and in certain nutraceutical applications, unlike less soluble or more toxic derivatives.

Q5: What is the projected timeline for potential pharmaceutical breakthroughs involving selenious acid?
A5: Early-stage clinical trials and research outcomes suggest potential for breakthrough therapies within 5–10 years, contingent on regulatory approvals and funding.

---

Key Takeaways

• Market Growth: Driven by increasing demand in nutraceutical and therapeutic sectors, with a CAGR projected at approximately 6.5% over the next decade.
• Regulatory Complexity: Tight safety regulations necessitate careful dosing and manufacturing protocols, influencing development timelines and costs.
• R&D Priority: Investment in selenium-based drug research is high-risk but offers significant potential returns upon successful commercialization.
• Supply Chain Strategy: Diversification and technological innovation are critical to mitigate geopolitical and resource limitations.
• Competitive Edge: Focused partnerships and proactive regulatory engagement can accelerate market entry and adoption.

---

References

[1] Mintel. "Nutraceutical Market Report," 2022.
[2] Euromonitor International. "Global Supplements Industry Outlook," 2023.
[3] U.S. Food and Drug Administration. "Guidance on Selenium Supplements," 2022.
[4] BCC Research. "Market Opportunities in Selenium Compounds," 2023.
[5] NIH. "Selenium and Human Health," 2023.